Novo Nordisk Announces Semaglutide Price Reduct...

By João L. Carapinha

February 26, 2026

Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per ...
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Revised MenACWY Vaccination Strategy for Adolescents in Germany
Genotype ECG Prediction
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency